Subject category:
Strategy and General Management
Published by:
Babson College
Version: 26 June 2001
Length: 14 pages
Data source: Published sources
Share a link:
https://casecent.re/p/21964
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
This is the fourth of an eight-case series (301-146-1 to 301-149-1 and 302-037-1 to 302-040-1). This case describes California-based Genentech, a worldwide leader in biotechnology and the first company to bring a biotechnology product to market. The case provides an overview of products on the market during the period 1998-1999, and also of research and development in key therapeutic areas. Strategic alliances and financials are also reviewed. One in a series of eight cases drawn from public information sources. May be used alone or with others in the series Global Biotechnology Winners. Suitable for graduate MBA and executive level courses in strategy, corporate strategy, and strategy relating to biotechnology and pharmaceuticals.
About
Abstract
This is the fourth of an eight-case series (301-146-1 to 301-149-1 and 302-037-1 to 302-040-1). This case describes California-based Genentech, a worldwide leader in biotechnology and the first company to bring a biotechnology product to market. The case provides an overview of products on the market during the period 1998-1999, and also of research and development in key therapeutic areas. Strategic alliances and financials are also reviewed. One in a series of eight cases drawn from public information sources. May be used alone or with others in the series Global Biotechnology Winners. Suitable for graduate MBA and executive level courses in strategy, corporate strategy, and strategy relating to biotechnology and pharmaceuticals.